 |
|
Evidence-Based Treatments for Alcohol Dependence
New Results and New Questions
Henry R. Kranzler, MD
JAMA. 2006;295:2075-2076.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
An estimated 8 million adults in the United States have alcohol dependence.1 Of this number, only a minority ever receive treatment for the disorder, even when treatment is defined broadly to include participation in Alcoholics Anonymous. Of the alcohol-dependent individuals who receive treatment, only a small fraction ever receive a medication specifically approved by the US Food and Drug Administration (FDA) to treat the disorder.
In 1994, the FDA approved naltrexone for the treatment of alcohol dependence.2-3 This followed by nearly 50 years the approval of disulfiram, which was approved prior to the modern era of efficacy review. Meta-analytic studies of naltrexone have shown that the drug reduces the risk of relapse to heavy drinking and, to a lesser extent, the frequency of drinking.4-5 In 2004, following use of acamprosate in Europe for more than a decade, the FDA approved this drug for treatment of alcohol . . . [Full Text of this Article]
Author Affiliation: Department of Psychiatry, University of Connecticut School of Medicine, Farmington.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
, , , , , , , , , , , , , , , , , , , , and
JAMA. ;295():2003-2017.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Preclinical Development and Clinical Implementation of Treatments for Substance Abuse Disorders
Pechnick et al.
Focus 2007;5:151-162.
ABSTRACT
| FULL TEXT
|
